HOME > Projects > Immunopharmaceutical Development Unit

D-5

Immunopharmaceutical Development Unit

8F

0801B

Developing therapies that target specific splicing variants

"Alternative splicing" is a mechanism of producing multiple products (proteins) from a single gene. Different versions of proteins from the same gene are known as isoforms. Combining different components (splicing) results in a different protein, known as an "alternative splicing variant (ASV)," and different isoforms are created in a process known as splice variant switching. Alternative splicing allows a multicellular organism to have cells with different morphologies and functions, and it is closely related to several pathologies. The aim of this research is to selectively inhibit only ASVs that are associated with a pathology (a chronic condition such as cancer, heart failure, arteriosclerosis, kidney failure, or diabetic retinopathy) while not inhibiting physiological ASVs. Selective inhibition of ASVs should allow safer and more efficient therapies.

Responsible Departments

Department of Clinical Gene Therapy

Research Partner

Periotherapia CO.

Project Members

Principal Investigators

SANADA Fumihiro

Endowed Chair Associate Professor

Department of Clinical Gene Therapy

Profile

 

TANIYAMA Yoshiaki

Guest Professor

Department of Clinical Gene Therapy

Members

MURATSU Jun

 

Department of Geriatric and General Medicine

OTSU Rei

 

Department of Clinical Gene Therapy

BRULE May Kanako

 

Periotherapia CO.

SHIBATA Kana

 

Periotherapia CO.

←back